SANGAMO THERAPEUTICS, INC. - Annual Update

I’ve put together this plain-English guide to help you understand Sangamo Therapeutics’ performance over the past year. My goal is to break down their latest filings so you can decide if this high-stakes biotech company fits your investment strategy.

1. What does this company do?

Sangamo uses advanced gene-editing technology to treat diseases at the DNA level. Because they are still in the research phase, they do not sell any commercial products and have no steady income from sales. Instead, they rely on strategic partnerships with companies like Pfizer and Genentech, earning money through upfront payments and research funding.

2. Financial Health: The "Going Concern" Warning

Sangamo reported a net loss of approximately $338.5 million in 2023, compared to $255.4 million in 2022. As of the end of 2023, the company held about $107.5 million in cash and investments. Due to their high rate of cash burn, the company has issued a "going concern" warning, signaling a significant risk that they may run out of capital within the next year without securing additional funding.

3. How they are staying alive

Sangamo relies on external capital to fund operations. As of March 2024, the company had approximately 156 million shares outstanding. To maintain liquidity, they recently completed a $100 million stock offering. While this provides necessary cash, it also increases the total number of shares, which dilutes existing shareholders and reduces the ownership percentage of current investors.

4. Major Wins and Challenges

• The Wins: The company’s lead project, isaralgagene civaparvovec (ST-920) for Fabry disease, is the primary focus. They have completed a Phase 1/2 clinical trial and are currently engaged in discussions with the FDA regarding the regulatory pathway for approval.
• The Challenges: The path to commercialization remains uncertain. The FDA has requested additional data regarding the durability of the treatment and manufacturing processes. Should the FDA require a large-scale, expensive clinical trial, the company may face significant financial strain, potentially forcing them to seek further partnerships or scale back development.

5. Key Risks

• The "Going Concern" Risk: Because the company is not yet profitable, they are entirely dependent on the capital markets. If investor appetite wanes, the company may struggle to raise the funds necessary to continue operations.
• Clinical Trial Failure: Gene-editing technology is complex and unproven at scale. If the FDA determines that the treatment is not safe or effective, the company’s valuation could decline sharply, as they have limited alternative projects in advanced stages.
• Dilution: To bridge the gap to profitability, the company will likely need to issue more stock. This creates a hurdle for investors, as the company’s total value must grow significantly just to offset the impact of the increased share count.

6. Future Outlook

Sangamo is currently in a "make or break" period. Their survival hinges on successfully navigating the regulatory process for their lead drug and securing enough cash to reach that milestone. Management is currently focused on cost-cutting measures and workforce reductions to prioritize their most viable projects. If they cannot secure sufficient funding, they may be forced to explore strategic alternatives, such as selling the company or its assets.

---

Investor Takeaway: Sangamo is a high-risk, speculative investment. Success depends entirely on the clinical and regulatory progress of their Fabry disease program and their ability to manage a very tight cash runway. Before investing, consider whether you are comfortable with the high probability of further share dilution and the binary nature of their clinical trial results.